SunHo Biopharmaceutical
SunHo Biopharmaceutical is a China-based biotechnology company that leads 5 cancer trials in OnCo, testing the immunocytokines IAP0971 and IBB0979 and the antibody IBD0333 in non-small-cell lung cancer, gastric & gastro-oesophageal junction cancer and advanced solid tumours.
Overview
SunHo Biopharmaceutical discovers, develops and commercialises biologics that modulate the immune microenvironment through the innate and adaptive immune systems, including immunocytokines and antibodies for cancer and autoimmune disease. It runs three proprietary platforms (antibody-cytokine fusion, ADCC-enhanced antibody and innate-immune multispecific) and its own GMP manufacturing facility in Nanjing, and is listed in Hong Kong. On ClinicalTrials.gov it is the lead sponsor of 5 trials recorded in OnCo (1 in phase 3 or 2/3): NCT06223841 (phase 1/2, A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors), NCT06581419 (phase 1/2, A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors), NCT05991583 (phase 1/2, A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors), NCT06292208 (phase 1/2, A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors) and NCT06504732 (phase 2/3, To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Scorecard
All companies- phase 3 +3
- targets +2
- modalities +2
- registry trials +4